BioVie Inc (BIVI)

[DJPele]

BioVie Shares Double After Positive Data for Parkinson's Disease Treatment


BioVie shares doubled to $2.89 in premarket trading Friday after the company said its Phase 2A study of NE3107 suggested improvements in non-motor symptoms in patients with Parkinson's disease.

The company said these findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.

NE3107-treated patients experienced a significant improvement for the sleep/fatigue domain of the Non-Motor Symptom Scale in Parkinson's disease, whereas placebo patients experienced a worsening.

Sleep/fatigue domain improvements correlated with motor score improvements. More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.


https://www.google.com/amp/s/www.marketwatch.com/amp/story/biovie-shares-double-after-positive-data-for-parkinson-s-disease-treatment-6fca8fee